Efficacy and Safety of MOX/ALB Co-administration

Inclusion Criteria: * Aged between 12 and 60 years * Written informed consent signed by either parents/caregivers for underage adolescents (aged 12-17 years) or by the participant him/herself (18-60 years of age); and written assent by underage participant * Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and at follow-up assessment 14-21 days after treatment * Willing to be examined by a study physician prior to treatment * At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 48 EPG Exclusion Criteria: * Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO) upon initial clinical assessment * Known or suspected infection with Loa loa * History of acute or severe chronic disease * Abnormal liver function assessed by multiple biochemical blood-based analyses * Recent use of anthelmintic drug (within past 4 weeks) * Attending other clinical trials during the study * Pregnancy, lactating, and/or planning to become pregnant within the next 3 months * Known allergy to study medications (i.e. albendazole, ivermectin or moxidectin) * Taking medication with known contraindication to or interaction with study drugs